NewAmsterdam Pharma (NASDAQ:NAMS) Hits New 1-Year Low – Should You Sell?Defense World · Oct 16, 2026
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Oct 2, 2026
NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer's DiseaseGlobeNewsWire · Sep 29, 2026
Menarini Group y NewAmsterdam Pharma reciben la aprobación de la Comisión Europea para Ubeslo® y Evlarco®PRNewsWire · Sep 23, 2026
NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)GlobeNewsWire · Sep 21, 2026
Biogen (NASDAQ:BIIB) versus NewAmsterdam Pharma (NASDAQ:NAMS) Financial AnalysisDefense World · Sep 11, 2026NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 5, 2026 | -$0.48 | -$0.52 | Miss |
| May 7, 2026 | -$0.46 | -$0.40 | Beat |
| Feb 18, 2026 | -$0.43 | -$0.63 | Miss |
| Nov 5, 2025 | -$0.38 | -$0.61 | Miss |
| Aug 6, 2025 | -$0.52 | -$0.15 | Beat |
| May 8, 2025 | -$0.45 | -$0.49 | Miss |